A (possible) solution to Covid-19
tillett.info
tillett.info
I'm wondering how we may rule out this worst case scenario.
[1] Is COVID-19 receiving ADE from other coronaviruses? https://www.sciencedirect.com/science/article/pii/S128645792...
[2] New blood tests for antibodies could show true scale of coronavirus pandemic https://www.sciencemag.org/news/2020/03/new-blood-tests-anti...
Hard to rule out worst case scenarios, we just have to work with what we have and make hard choices.
This is at least partly why there are no SARS/MERS vaccines. There's a paper I'll try to dig up where 4-8 (can't remember) modified vaccine candidates were tested in multiple animal species, and in each case except one, immunity was conferred but exposure to the virus lead to a dangerous autoimmune response which destroyed lung tissue.
"Instead, it [SARS-CoV-2] appears to be no more concerning than the influenza virus." The citation for this claim is an article in Canada's National Post.
Three things that jump out at me:
a) You'll get more credibility from having a thorough lit review than from listing credentials. Linking to magazine articles from journalists on genetic variations, when there's academic research to cite, is a little bewildering.
b) You don't identify something harmless by just testing asymptomatics. This is counterintuitive, but a great example of the Wason selection task:
https://en.wikipedia.org/wiki/Wason_selection_task
You would probably want to survey the rate of variants in asymptomatics in a certain community, then compare that with the rate of variants in fatal cases in the same community to look for significant differences (and be fully prepared not to find any significant differences beyond chance, a real and likely possibility).
c) I'm still not sure what the author is specifically recommending we do next. Researchers are looking for functional variants, we don't have one to distribute yet, so we should do more sequencing. Ok, great. From what populations? How many geographic areas? Where do we get the samples? There are bottlenecks in sample collection, how do we overcome those? Given (b), how can we get more samples from fatal cases, to compare virulence to those in the general population? Task overloaded hospitals to send us additional samples from dying patients? Is there another way we can get this info?
I don't want to dismiss this out of hand, this might be a good area for additional focused research. I do think there are some key unanswered questions though, and currently a worrying disconnect with the current state of research on variants.
EDIT: Daniel, I know you're going through the comments here, and some of them have gotten pretty harsh, sorry for that. I genuinely hope you're on to something, and are able to continue to refine the post into a more robust and specific proposal using all this feedback, despite the tenor of some of the comments. That's really the best case for all of us, so good luck.
a) The post was intended for a lay audience, not other scientists directly. The reason I didn’t write a scientific paper on this is it would sink without a trace as most scientists and doctors are too conservative. It is quite a radical idea and while scientifically sound, it will take mavericks outside of science to see this done. For better or worse it will take the efforts of someone like on of the tech billionaires to push this forward.
b) If I had to choose one aspect that gets most commonly confused by people who read the idea it would be the reason for searching only mild/asymptomatic cases. This is purely an efficiency issue. In an ideal world we would sequence the strains in all cases, look to see if we can find mutants with deletions, and then see what was the clinical outcome of those infected with that strain. If we find that all cases of a particular mutant are mild/asymptomatic then we would have our candidate.
Because we live in a constrained world where it is not possible to sequence all cases, where should we first look? Since we are looking for a mutant that only causes mild/asymptomatic cases we can exclude patients with serious symptoms as a first pass. Once we find a candidate strain that has the right sort of mutation we can then sequence all cases in the local area, both serious and mild to get the full clinical picture. This will make the search much more efficient.
c) I am recommending that we put b) into action and get on with specifically looking for an attenuated (only causes mild disease) strain ASAP. If we find one then we can discuss what to do next, but the first step is to get started.
The good news is this can be done quickly and relatively cheaply provide we have the will and the support of someone with the clout to make it happen. It won’t be easy, but it can be done.
True, but I think you are missing part of Daniel's proposal. You don't "just" check for unique variations of the virus in asymptomatic carriers, you also check the sequence for major deletions: We would ideally be looking for a virus strain with a large(ish) deletion in an essential viral gene. This sort of mutation is easy to spot in the SARS-CoV-2 genome data, and because the genetic information has been removed, it makes the virus very unlikely to be able to mutate back into a dangerous strain. Ideally, the strain identified will have infected a number of other people in the local area too so we can know it is safe.
So while you do want to verify that the sequence is not also present in "serious" cases, you are prescreening by a factor that theoretically should correlate to severity. Whether you "need" to do additional testing depends on your assessment of base risk. If you assume that almost everyone is going to be infected with a powerful strain if you do nothing, doing your testing in live cases with a strain you suspect is mild might still be justified. Ideally (as quoted from Daniel) this "testing" might be mostly satisfied by just monitoring those already infected by the original carrier(s) with the same mild strain.
The idea in the post is obviously a good one if it can be done, it's just that it seems like a generic idea that should be considered for any viral pandemic, which makes me wonder why it's not already an approach people are working on.
As for why people aren’t working on this idea I don’t know. Maybe someone is and they will send me an email and I can update my post. I would certainly be extremely happy with this outcome.
> This data suggests a simple and testable hypothesis – there are natural strains of SARS-CoV-2 in the world that have mutated to be non-pathogenic (asymptomatic), but are still infective and will provide immunity to the more pathogenic (deadly) strains.
From the structure of the post it sounded like "this data" referred to Iceland plus the Wuhan study.
If you only meant the Wuhan study then apologies for misunderstanding.
Can you provide peer / concept review from virologists?
A few items of feedback:
- You could use a title that includes a distinct word to identify your proposed solution: "Using accentuated COVID-19 strains as a (possible) solution". This helps people to communicate and refer to the idea concisely.
- The top three paragraphs may be known to your target audience; consider allowing the reader to get straight to your point.
- It took me a while (certainly to the Q&A section) to grasp that attenuated virus strains are different from dangerous ones. Explaining this (perhaps in a brief sentence, then repeated and elaborated in a more detailed paragraph) near the top may also help.
- Further references (especially peer review from respected authors) may help gain traction. Decision makers can be -- sensibly -- risk averse in global crises like these.
Good luck!
It is not risky to go looking for a naturally attenuated virus. This is the first step that needs to happen.
My suggestion is really one around building trust - it'd help to have others in the same scientific field confirm and/or question the approach.
While you do not recommend ZJ01 due to the potential for it to mutate back into the original strain, isn't it also quite dangerous?
That would likely remain a primary concern for many - we musn't cause large scale harm intentionally. And if we don't know what effects a strain has, it makes it ethically difficult to distribute.
From the ZJ01 Medrxiv[1] page you link to:
"We found, in our 788 confirmed COVID-19 patients, the decreased rate of severe/critical type, increased liver/kidney damage and prolonged period of nuclear acid positivity during virus dissemination, when compared with Wuhan."
[1] - https://www.medrxiv.org/content/10.1101/2020.03.10.20033944v...
> (1) The term "drug" means… (B) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals;
CBER would be the responsible center for the FDA. Other countries have analogous regulations.
Could you come to market with a naturally attenuated strain? Yes. Would it take less time? Not really, because you don’t get to do an “end run around the regulations” as you put it in another comment. The logistics of making sure it works and then setting up the supply chain and quality systems are what take the most time. There are no shortcuts in medicine.
Personally I think the regulatory authorities would rapid approve it based on the epidemiology data collected in the process of finding the strain. The FDA has already shown that it can move faster than its usual glacial pace given sufficient motivation.
The much more important question is when are we going to start seriously looking for such a strain?
There are many teams all over the world that are looking for less deadly (and more deadly!) strains to guide development of therapies. They’re too busy right now to post on message boards or speak to reporters. It’s however extremely unlikely that a less deadly strain will become the therapy, although it could be the basis of a therapy (but I think this too is unlikely).
It sorta strains reason to argue that none of these people thought of looking for an attenuated strain.
Isn't the simpler truth just that finding one takes a lot of ground work that's already being done, but hasn't born fruit yet?
Maybe the feds could allow states to get a waiver from FDA regulations if they want to try things like variolation.
This would still require someone at the federal level to stick their neck out a little, but (I think) a lot less than if they were to propose something like this as a federal policy.
We've got a federal system, let's make some use of it.
The process of finding any useful strain is going generate good data that it is safe anyway.
Natural selection versus bureaucracy!
Going after covid-19 genomes in a group of asymptomatic and symptomatic 70+ years old with sampling from different regions/countries may give us better data.
Finding a mutated strain which never gives symptoms in old people from diverse locations, diet, health status etc. is the holy grail of this approach.
How about 10 to 50 million ?
I live in Nigeria. Between December and late February, many people in Nigeria and Ghana report experiencing symptoms similar to those that could be caused moderate COVID-19 infection. These included, fever, diarhoea, cough, sore throat, malaise.
Many physicians and scientists I know think it we may have had a mild outbreak of the disease. If so, was this reduced severity due to a mild strain of the virus or to other factors ? It warrants investigation. Your proposal and the theory underlying it make a lot of sense.
I would really like to be able to dig deeper into this.
Who is going to be the person to recommend deliberately spreading that strain to the world population, knowing that 0.1% of the world, 7 million people, will end up in a hospital and die?
Sure, overall, fewer people might die, but the reality is whichever world leader makes that call has effectively just signed a death warrant for 7 million people. That isn't the way to get re-elected.
Happy to answer questions about the idea, but I am most interested in find collaborators to make it happen ASAP.
No guarantees (they are all swamped). I hope they respond and put you in touch with the right people.
The upside is, you may draw other very interesting conclusions while collecting data for this mission, and be able to "pivot" if you will.
Can you provide any evidence to back up this statement? If you were to start intentionally infecting people with a (naturally) attenuated strain claiming that it will confer immunity I suspect authorities would request you get regulatory approval.
If you're approach does require regulatory approval. What advantage does your approach have over those currently in developement? Some of them are just bits of the virus (mRNA that codes for the spike protein) packaged with a delivery mechanism [1].
It's a plausible approach, that has been tested in animal studies. There are a number of other, similarly plausible vaccines entering human trials.
It is however deemed to be too high risk to just start giving the vaccine to large numbers of people. So the vaccine will have to go through (an accelerated) trial process. It will then likely be given to at risk groups (health care professionals), before becoming widely available. Most experts expect this to take at least 16 months (which would be a world record).
Your approach would have the same issues as are present with any other vaccine.
If regulatory authorities are willing to skip trials for your approach, then the same should apply to other vaccines under development.
[1] https://www.modernatx.com/modernas-work-potential-vaccine-ag...
Even if you wanted to go down the regulatory pathway for some reason it still has a number of advantages over other approaches.
1. We would know it is safe in humans before we began.
2. We would know what mutations make the virus less pathogenic.
3. Once used it would drive the pathogenic strains to extinction.
4. It will be work in poor countries that can’t afford or distribute a conventional vaccine.
5. It will infect and protect those that are not deliberately infected through contact with others.
If you were to start doing this without regulatory approval, the most likely outcomes seems that you’d be arrested [1]. Do you have anything that suggests otherwise?
> 1. We would know it is safe in humans before we began.
The regulatory requirements for “knowing it is safe in humans” are currently quite high. As things stand, I would expect trials to be required. Can you provide any evidence to suggest trials wouldn’t be required?
You want to know how the vaccine effects individuals with pre-existing conditions etc. etc. And, as there’s always some risk, you want to be sure that the vaccine is effective.
> 2. We would know what mutations make the virus less pathogenic.
Large scale sequencing of the virus, in individuals and populations will be interesting. Being able to link this patient outcomes is also interesting. And might help in vaccine development. It would be interesting to have a large dataset of viral sequences from asymptomatic individuals. Can we see clear differences between asymptomatic and symptomatic individuals? This would be an interesting dataset, but I’m not sure that the results would be as clear as “look this deletion exists in a sub-population of asymptomatic individuals”. Would be a cool dataset and an interesting project though. There seems to be a lot of NGS data [2] available. This might be a suitable starting point for such a project.
> 4. It will be work in poor countries that can’t afford or distribute a conventional vaccine.
If a vaccine is available, then I suspect there will be sufficient international support to make it widely available. Having an active outbreak anywhere in the world would likely be deemed an unacceptable risk, given the potential for further mutation.
[1] https://www.theverge.com/2020/3/26/21195236/fbi-doj-arrest-f...
0. https://www.biorxiv.org/content/10.1101/2020.03.11.987222v1....
Note: asymptomatic at the time of testing. They may still develop symptoms over time.
https://www.icelandreview.com/sci-tech/is-icelands-coronavir...
The best way to find a solution is still try to understand how it acts on different types of people and if they have underlying previous conditions what changes it does, this takes time and I believe that’s the reason there isn’t any cure except by chance in a short time.
https://www.straitstimes.com/asia/east-asia/mystery-of-long-...
Apparently 80% of those tested later get symptoms: https://twitter.com/TonyBurnetti/status/1246258723774963713
If we can find a strain that just makes you feel like you have a cold that you get over in a week or so then that is what we want.
It's pretty confusing when symptoms are below a critical threshold and you don't have a test yet.
The conclusion is that the prevalence of asymptomatic cases is about 0,32%, CL95 is 0,12-0,76%.
Link (in german): https://www.sora.at/nc/news-presse/news/news-einzelansicht/n...
[1] https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhets...
[2] https://www.land.nrw/sites/default/files/asset/document/zwis...
[3] http://www.igmchicago.org/wp-content/uploads/2020/04/Covid_I...
On top of that, other research indicates some folks might be recovering without developing antibodies at all (they could be clearing the infection with only their innate immune systems). In that case we couldn't be totally sure about the upper bound anytime soon:
https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v...
The next study that is currently being prepared will include antibody-tests, but it seems logistics and which test to use is not a trivial matter.
We are looking for an attenuated strain and that will be found in people with a mild case. We could sequence all cases, but we would exclude any strain that puts someone in hospital so it is a waste of resources to sequence viruses from people in hospital. From a practical perspective it is better to concentrate on people with only mild cases.
If I pick 1k people with mild cases at random, I will find pretty much any strain that currently is in circulation. How do I know which strain is harmless?
politicians aren't stupid, they just play a different game and it looks really dumb from the outside. for them, their moves make sense, they're pros at it.
anyway, you've done very well to find yourself on the top 30 of HN. the smarter press reads this directly. the less smart press reads it a few days later after it spreads through the net via reddits, facebooks, etc. hopefully it's a matter of time a good headline will find its way to pair of eyes in the right place at the right time.
- No one will want to be the one "deploying" the attenuated strain in a human and then be responsible for some unforeseen death (even if it's just 1 in a billion). Utilitarianism is not widespread nor socially accepted. Even less so in politicians, who are quite risk averse.
- There is no lobby supporting it. There's no $$ to be made and the "vaccine" is basically free.
I would give them more credit, especially in a situation where the status quo includes so many deaths. I was impressed with how readily most states licensed self-driving vehicles, knowing that there would certainly be deaths. Their rationality here likely came from seeing tens of thousands of people dying on the roads each year.
And it would not be free, you still need to collect this strain, replicate it at massive scale and then distribute it.
1) Wouldn't natural selection result in a milder strain crowding out a more deadly strain? After shelter in place lifts, people with a mild strain will be more likely to go out and spread the virus whereas people with the deadly strain will be more likely to stay home sick.
2) Is there any consensus on whether we become immune to COVID after getting it (e.g. if we get a mild strain will we really be immune to a deadly one)? I've heard different opinions and I'm wondering what the leading hypothesis is at the moment.
Thanks!
Myron said, "I see that Lee Flowers is playing today after a high ankle sprain 2 weeks ago. But I thought that high ankle sprains took 4 weeks to heal. What gives?"
Coach Cowher replied, "4 weeks is true, Myron, for the first high ankle sprain. But if you recall, Lee had a high ankle sprain on the same foot last year. And since subsequent high ankle sprains only take 2 weeks to heal, he's ready to play."
Myron paused and asked, "Then why don't you just take the whole team out in February and sprain all their ankles?"
(We laughed 20 years ago. Nobody's laughing today.)
Sadly joints tend to work a bit differently from the immune system (with some exceptions).
Also it is a paper from Singapore which should avoid the China negative bias.
Yes. And how would that compare to the various trillions in stimulus to keep a choking world economy afloat, never mind the deaths that could be avoided?
I don't understand posts like this, they say "if we had a good solution, how could we possibly use it?"
One reason I was wondering is that manually administering the virus to people seems more akin to a vaccine in nature.
Actually once a safe strain was identified it would be impossible to stop people spreading it on their own. People would test to make sure they had the safe strain and then invite everyone they knew around for tea and scones.
Yes, but this doesn't seem too hard. Just have some infected people spit in a cup, and mix it into large vats of raspberry jam and people can then just spread it on their toast on one morning.
https://www.fda.gov/food/food-safety-during-emergencies/food...
More likely, viral load, immune system strength, overall age and the genetics of the person infected are what determines if the infection is fought off before any symptoms are shown
Developing attenuated-virus vaccines is by screening serially propagated SARS-CoV-2 for reduced pathogenity has also been suggested already.
1. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines https://www.nature.com/articles/s41541-020-0170-0
2. Regla-Nava, J. A. et al. Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates. J. Virol. 89, 3870–3887 (2015). https://www.ncbi.nlm.nih.gov/pubmed/25609816/
Authors idea of spreading the attenuated virus is based on the idea that if the immediate COVID-19 disease can be avoided, increasing viral load in population is smaller risk. I think that's the weak point. If the vaccine is developed and the virus establishes itself in the population, the number of people getting infected will be lower overall and less people will get severe disease due to natural immunity + vaccine.
ps.
> appears to be killing between 1% to 3.5% of the people it infects
Author is confusing case fatality rate (CFR) with infection fatality rate (IFR). Infection fatality ratio seems to be something like 0.6% according to recent estimates. IFR estimates seem to go down over time.
These numbers on the death rate are not mine, but what has been reported in the scientific literature. Probably the best numbers come from South Korea where they have done a pretty good job of tracking down everyone infected. There the fatality rate is around 1.8%.
Even if the true death rate is 0.6% that still means the deaths of nearly 50 million people worldwide.
It is worth comparing this to things like SARS. The distribution of SARS symptoms would be pretty narrow - everyone gets really sick. So the variance for SARS is small compared to Covid-19. The same could be observed for influenza or rhinoviruses.
The problem with a "milder" Covid-19 is that it might still have the same massive variance in symtpom severity. It might kill less people, but it would still be morally bankrupt to let it spread. In fact, it might be preferable to not reduce the mean severity, but just decrease the variance so it never gets nasty enough to kill without being immuno-compromised.
https://www.medrxiv.org/content/10.1101/2020.03.28.20036715v...
> In cell culture, DRACO was reported to have broad-spectrum efficacy against many infectious viruses, including dengue flavivirus, Amapari, and Tacaribe arenavirus, Guama bunyavirus, H1N1 influenza, and rhinovirus, and was additionally found effective against influenza in vivo in weanling mice. It was reported to induce rapid apoptosis selectively in virus-infected mammalian cells while leaving uninfected cells unharmed.
They even had a crowdfunding campaign on Indiegogo[2] but as usual, nobody cares about infectious diseases until the pandemic...
Now the crowdfunding seems moved to another page[3]
[1] https://en.wikipedia.org/wiki/DRACO
Bill Gates would like a word.
"However, research on DRACOs has entered the well-known “Valley of Death” in which a lack of funding prevents DRACOs, and many other promising new drugs, from being developed and advancing toward human medical trials. To progress DRACOs research it needs to be demonstrated against clinically relevant viruses (i.e; HSV). To that end an IndieGoGo campaign (http://igg.me/at/EndTheVirus) was started on October 13, 2015."
They don't seem to elaborate on what the hell they mean by the valley of death.
https://www.straitstimes.com/asia/east-asia/mystery-of-long-...
If COVID-19 is human malware, then this is a human software update.
Of course you might find the best strain you can find exists in 100% of asymptomatics and 20% of the dead. That would indicate your strain has some non-zero death rate.
Today we prefer to immunize with a part of the virus structure, which end up doing the same thing.
> The reason why is immunity to respiratory viruses (like corona) doesn’t last long – 6 months to 2 years.
I haven’t read anything like this before. It seems like you’re extrapolating from the flu vaccine, which doesn’t last because the flu mutates too quickly. Coronavirus mutate much slower and the thought is that we’ll likely only need one vaccine. Have we actually found any less deadly strains? My understanding is that there have been mutations, but all are small and as far as we can tell superficial. You would likely need to create such a mutation and then you’re back in vaccine trial territories, except dozens of labs that are experts on this have a head start.
> If humans do develop immunity, how long does it last?
> That’s another big unknown. Immunity is short-lived for the coronaviruses that cause common colds; even people who have high levels of antibodies against these viruses can still become infected, says Stanley Perlman, a coronavirologist at the University of Iowa in Iowa City.
> The evidence is more equivocal for the two other coronaviruses that have triggered epidemics: those that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Perlman says his team has found that after people recover from MERS, their antibodies against the virus drop precipitously. He also says that his team has gathered data — not yet published — showing that SARS antibodies are still present in the body 15 years after infection. But it’s not clear whether this immune response is enough to prevent reinfection. “We don’t have good evidence of long-lasting immunity, but we also don’t have really good data from both SARS and MERS,” Perlman adds.
There is no need to create any viral mutants in the lab (and all the difficulties this will involve), just use what is already out there in the community. We just need to go and look for them.
A few questions:
- How about the dengue fever scenario? (Immunity to less pathogenic strain can cause more severe reaction with a different strain). Can we asses the risk somehow?
> Apart from the time it will take to develop, trial, and mass produce a vaccine (12-18 months), it is unlikely that any vaccine will be practicable. The reason why is immunity to respiratory viruses (like corona) doesn’t last long – 6 months to 2 years
Is there any proof that this is the case with this virus?
Is is possible to do the infection outside the human body?
Another interesting possible solution which can be used now but is a bit unproven is to use hydroxychloroquine + zpak + zinc or some variation on that on people with symptoms or who test positive as it seems to reduce viral spreading.
Bit controversial but the results in Marseille look quite good - the infection rate in those tested has roughly halved recently while France as a whole is going up. https://madeinmarseille.net/64805-covid-19-didier-raoult-res... https://www.mediterranee-infection.com/covid-19/
And the anecdotal reports from the Zeleko guy are good even if people think he's a nut.
Also in the Rome area "every single person with Covid-19 that has early signs, like a cough or a fever for example, is now being treated with the anti-malaria drug." Which may provide data going forward https://www.trustnodes.com/2020/03/29/italy-finally-starts-m...
Anyway unproven but may be a way forward if the results prove good.
This is not really anything unusual and is exactly how viral live vaccines work. The vaccine for live polio and measles work exactly this way.
Here in South Africa, we are really unsure if our lockdown is having the a meaningful effect.
I think this is a great idea to get community involvement upon. I'm sure you know there's a network of researchers on Twitter (I'm aware of the one centered around the Krogan lab in UCSF i.e. @KroganLab), and on Reddit (reddit.com/r/covid19) that have been posting ideas back and forth. Consider posting there.
I like your idea because it circumvents a number of ethical issues, but may be time/resource consuming. Another approach but one that quickly hits those ethical issues during testing would be to knockout immunosuppressant genes as popularly described by: https://www.nytimes.com/interactive/2020/04/03/science/coron... (preprint https://www.biorxiv.org/content/10.1101/2020.03.22.002386v3....). Perhaps mice model? An in between approach that might be better, would be to target your search by looking for changes that likely inactivates the immunosuppressant genes.
I and I'm sure many others dearly hope your approach works. Godspeed sir.
It doesn’t really matter to us today if this virus eventually becomes less dangerous in the next 500 years. We need to speed things up a little.
it isnt killing, but it's isolating them, preventing its spread
In fact, with existing attenuated virus approaches that eventually becomes the problem, the "last mile" of this approach usually sees you needing a real vaccine to cap off the disease. Otherwise the virus kinda circulates around in a tight enough cycle that you see most if not all eventual mutations including dangerous ones that kill. Communities using attenuated virus vaccination approaches for Polio faced this in recent times, for example. And it becomes a problem in places where you can't get people to afford or accept the real vaccine.
Anyway it's a tried/tested approach to solving a pathogen problem, so it's hardly some crazy idea this person has. They do point out the there will be specific types of mutations that are less likely to mutate back if you read the whole article.
This problem is easy to avoid these days.
You may have the best idea in the world, but your presentation is terrible, the rambling is terrible, the assumption you are the only person to think of this is terrible and the urge to get the attention of someone important to pay for it is terrible.
The sad truth is you need to fit your idea into the size of a tweet, write the long version elsewhere linked. If you can't do that, someone else can and will and their idea will win over yours because you can't get attention rambling like that
And governments are never going to purposely infect their populations, if you think anti-vaxers are bad, imagine when people in the USA have the choice not to get the injection, 99% of the fox news viewers will refuse and the president will say "well you can if you want but I won't" (I mean he won't even stop shaking hands or wear a mask)
Skirting the regulations is pointless, because the important thing is the intent of the regulations. If it were just a problem with the regulations, we could also just change the regulations and give the untested vaccine.
Plus, if you want to argue from a pure legal background, this approach would probably still run into trouble, as in most countries it would be highly illegal to infect people on purpose.
Please take some time to read through the whole proposal again. I know this sound snarky, but yours is a really common response that has been addressed.
The question posed is would an attenuated virus create a much short immunity reducing efficacy of the overall approach. It seems like the only answer can be we don't know, we'd have to look at that.
Agreed 100%.
What about simply letting the people who young and healthy or immune go about their lives?
Letting the young and healthy get sick and then become immune is essentially using an attenuated human instead of an attenuated virus. Same outcome though.
This would both build herd immunity and keep the economy going.
Sweden has no quarantine and has been averaging around 400 to 500 new cases daily while UK quarantined everyone and has 4000 to 5000 new cases daily.
The interesting thing is that the UK has 60 million people while Sweden has 10 million people.
So according to those numbers...how effective is quarantine?
The young are basically immune to this.
I'm saying quarantine the vulnerable populations and let the healthy populations out.
The article that this text links to discusses case fatality rate, which is not the percentage of people the virus infects that die. This is a fundamental and very important difference, especially given that you later note the percentage of asymptomatic people.
Let’s not get caught up on the final death rate and let’s look at what we can do right now.
Most serious estimates of IFR are between 0.1 and 0.6%. The OP should be edited to either correctly state that COVID-19 kills between 1 and 3.5% of identified cases, or be updated to use numbers that are not misleading.
I suspect lots of young people would happily volunteer if it meant their life could return to normal. Heck, I'd bet even for the current strain, with a ~0.1% risk of death for young people, quite a few people would volunteer to get it if it meant they could get out of lockdown.
I personally work from home (as one of the privileged few being a programmer) and when I do go outside I take social distancing serious. My health in general isn't great although I'm not old (early 30s) and which is why I don't leave my apartment much anymore. I live in a college area and young adults are still going over to each others apartments and without practicing social distancing when going out to buy groceries. I'm in Quebec for context. I've heard it isn't much different in the USA.
Maybe the (possible) solution could work without young people on board.
That doesn't matter. The reason why everything is closed is hospital capacity. That impacts everybody. If you had a car accident you may not get all the help you need.
14% of people may need hospitalisation and you want to focus your efforts on that group. There is almost no young people there.
Source: https://nos.nl/artikel/2330036-nederlandse-coronapatient-hee...
NB: I am NOT a microbiologist and do not know how far this is related.
Plasma contains molecules that contribute to immunity. The donation transfers those molecules from the donor to the recipient. It doesn't directly confer any immunity to the recipient, it reduces the amount of virus circulating in their body, giving their own immune system more time to respond.
It seems very promising.
Maybe we can do that to a subset of healthy young population so that they can go back to work without risking others?
I don’t have much idea about either virology or molecular biology. Just curious.
> "No. Apart from the time it will take to develop, trial, and mass produce a vaccine (12-18 months), it is unlikely that any vaccine will be practicable. The reason why is immunity to respiratory viruses (like corona) doesn’t last long – 6 months to 2 years. We would have to keep vaccinating everyone in the world every year (or maybe every 6 months if we are unlucky). "
I am not sure I agree with this. I am taking the annual flu shot, along with all the members of my family. I would be fine with an annual, or semiannual, coronavirus shot.
> One thing is certain with the current situation is we need to take some risks if we are going to solve it quickly.
Looking for quick answers in a crisis is really risky. There is a natural push to try to get things back to normal as soon as possible, but developing an attenuated vaccine (even with a potential strain already in existence), takes a lot of time and testing.
I certainly agree that we should be trying to sequence every variation we can find in the wild, but even if everything works just right, it will take a lot of time. I haven’t followed enough of the reports, but how many strains have been identified thus far?
Another issue is that even just getting the reagents to collect and passage the virus is difficult as they are all needed for clinical testing. So working with live (even attenuated) virus is very difficult at the moment. But this highlights a reason why it is so critical to study these topics when we aren’t in crisis mode. Much of the current vaccine work has been adapted from earlier SARS-CoV research.
But this approach of finding a weakened strain (or generating one), is a good idea to be attempted in parallel. (I’m sure that someone is trying to passage the virus though a different host to attenuate it as we speak). The first step is to try and sequence as much as we can from the wild, but this has its own logistical difficulties. Hopefully there is a research study going on that is trying to collect as many samples as possible now, so that we can sequence later when things have calmed a bit (because there is likely going to be a second round).
I don’t intend to sound so negative on this. I largely agree that this is one avenue that needs to be studied. And from your background, I know you understand these risks/concerns. I worry about the larger public though. My main concern is that this concept can be very risky, especially with an already scared public looking for quick answers. Seriously, the last thing we need is people intentionally trying to get infected in the hope of getting a less lethal strain. This isn’t a cowpox scenario. I guess my hesitation comes down to me not liking the idea of taking too many risks for the sake of doing it quick. That’s been known to come back and bite people.
See links here: https://news.ycombinator.com/item?id=22799096
And the lack of testing to "save time" actually does not look like a good idea for a live virus you want to give to the whole earth.
Please correct spelling:
..I now work..
..a number of papers..
Thank you, please spread the word (url).
Please everyone if you know someone you think might be able to help make this happen then spread the word. You are even welcome to steal the idea and claim it is your own :)
Best of luck!
I might also mention that the virus doesn't really care about us. Mostly it's interested in infecting our bacteria. That's kind of a joke, but in reality, it says everything about how to control it.
Poorly informed, Japan did not even have restrictions in the first place.
Many possible vaccines for covid-19 are discussed in this paper [0] which is surprisingly accessible. There's a table [1] that depicts categorization of vaccine candidates and it does mention attenuated virus as a possible solution, the one in development by Codagenix and The Serum Institute of India [2] expected in the second-quarter of 2022.
2022 seems to be an eternity away, and the problems, as the paper points out, with attenuated vaccines are:
1. Requirement of a much wider phase 3 trial than other vaccine types.
2. Very time consuming to create such viral strains in the lab.
There are overwhelming advantages working in its favour, though:
1. Human vaccines using the same platform exist for other diseases.
2. Existing infrastructure can be used to ramp up trials, approvals, manufacturing, and administration.
The proposed solution by Dr. Daniel Tillett here makes sense because it turns those disadvantages on its head-- a substantial number of people might already have been infected with proven mild inflection and the strain(s) can be isolated at a much faster clip!
[0] https://www.cell.com/immunity/fulltext/S1074-7613(20)30120-5
[1] https://www.cell.com/action/showFullTableHTML?isHtml=true&ta...
You noted on your post "live attenuated (oral) polio vaccine" but later wrote "Apart from the time it will take to develop, trial, and mass produce a vaccine (12-18 months), it is unlikely that any vaccine will be practicable."
So how do you imagine this solution being administered if not as a vaccine? Is the solution a Pox Party (https://en.wikipedia.org/wiki/Pox_party) with someone verified to have the harmless strain?
You can look at it from the other perspective - once identified it would be impossible to stop people spreading it around on their own. Let’s say one of you friends got infected with this “safe” strain you would quickly head over to their home for a cup of tea and a good chat.
IANAL but I did run an infection detection medical diagnostics startup for 3yrs that I co-founded. Since we're on HN, perhaps here is how you might get traction (note, i'm just throwing this out move-fast-and-break-things-style for the sake of brainstorming):
1. Form a company, announce the idea bigtime! (Incorporate overseas for liability protection?)
2. Sell a sequencing service that tells you the strain you have -- offer no medical advice. Not a diagnostic for medical purposes, more like 23&me (does this get around regs?)
3. Offer a free matching service to find locals with the strain, perhaps with an app to validate their strain, etc. (some incentive for the customer?)
Note this isn't legal advice, but it would be awesome if someone with the correct background could provide feedback on this approach.
As for my startup, we sold overseas in easier reg jurisdictions -- we were never able to break into the US market.
We actually started clinical trials of the Moderna mRNA vaccine in humans a month ago. We may have some early safety data. Better that than intentionally exposing people.
Look up the history of vaccination. Starting in the late 18th Century, people used to do this exact thing for early vaccinations: they found a naturally occurring, less pathogenic strain (for instance, cowpox[1] in the days of smallpox), and intentionally exposed people. This is exactly the same thing as a vaccine except less controlled and, ultimately, much less safe.
.
[1]The root of "vaccine" is "vacca," i.e. Latin for "cow," for this reason.
Furthermore, I see a few problems with that idea :
- it seems very hard to create a truly harmless virus. Viruses still destroy cells to replicate, they cause immune system response, inflammation, what would happen to weak or immunocompromised people ?
- if immunity through vaccines lasts 6 to 24 months, why wouldn't this be the case here too ? You'd still need to develop a vaccine or keep infecting people with new strains of this virus
- why would the deadlier strain disappear ? Unless you also engineer the mild strain to be much more infectious, both strains would still spread equally in the population. Presumably the milder strain would be less symptomatic so it would in fact spread less
- it's not demonstrated in what way economic downturn would be more harmful in the end. Economy is a means not an end.
"Growth" is not the issue, but economic prosperity and stability is immensely important with respect to the well-being of the people. Economic downturns also reliably cost lives in a huge amount of different ways.
I'll consider this idea to be pretty whack until people smarter than me think it's a good idea. But I hope we can come to terms that it's worth discussing taking some health risks to limit economic downturns. "People's lives" vs "the economy" is a false dichotomy.
Other countries (some that may not care about the well being of their citizens) will be quite happy to take your place hierarchy and exert their influence over the world as they see fit, which may well be to the detriment to your nation (and nation is comprised of its people).
Also: Why is this faster than other methods of vaccine development already underway? Once developed, wide-scale manufacture & deployment is an enormous logistical challenge completely separate from R&D. Can this use existing vaccine manufacture & distribution channels?
It's difficult to really assess the viability of this plan without it taking into account many of these details. To my moderately-informed-outsider thinking (which lets face it, is the crowd the author was targeting by posting here on HN) it may suffer from the "ideas are easy, execution is hard" problem, because execution details apart from the actual R&D side are lacking. I'd like to hear more from the author on the topic though.
The reason why this would be faster is the process of looking for the strain and identifying it as safe would generate data that would allow the regulatory authorities to approve its use.
Manufacturing would not be the limiting factor here.
Your background also does not appear to contain detailed experience within the manufacturing and deployment side of vaccines, so I hope you'll forgive me if your lack detail on that end isn't mitigated by simply saying "Manufacturing would not be the limiting factor here" without further explanation.
You say you'd like to get this proposal in front of influential people, but why would Bill Gates assume the logistics are fine, not a problem, without you specifically addressing the issue?
And if I can't get answers to the questions I've raised after 1 full reading, one slightly faster reading, and an exchange with the author himself, then if I were a person of any influence I would not devote limited time to this proposal. Presumably you posted here to get such attention. Presumably you would engage a bit more and answer in greater detail if you knew I were someone who could help advance this in some way. (I'm not-- I have access to researchers in academe but no influence) But I don't see you getting the attention needed, not without a proposal that moves beyond the R&D phase in significant detail
Personally I find the lack of logistical details beyond the R&D and sequencing side of things indicate that your own business interests have you focusing on that end of the project to the detriment of other factors that need to be taken into consideration. Please note that I'm not saying you're doing this for the money: Only that your current area of professional endeavor is the area of the problem where you have focused your proposal, and the areas where it's lacking are not bolstered by your simple assertion of "they are are not a problem."
You have posted to an audience that is not automatically going to know how your R&D could be logistically deployed, but also an audience that knows ideas are easy, and execution is hard. If you wish to have your proposal widely accepted here, if you wish people here with connections to those who could influence anything, these are things you need to address.
Otherwise it could be dangerous if it mutates again to a more dangerous virus, even if not the original coronavirus (as you said we choose a mutation with a deletion).
Large deletion mutations don’t back mutate in practice.
So I suggest looking for a strain for which we have a mean of killing the virus, that is a weak virus for which we have a general vaccine for expected mutations, if that is possible.
So how are we gonna deal this increased liver damage then, if we are actually gonna use this less pathogenic branch of the virus as a quasi-vaccine?
Is there way to reengineer this virus so that it would be less kidney/liver damaging?
IIRC, the USA came very close to eliminating polio by switching between live virus vaccines and killed-virus vaccines several times.
Maybe someone who knows more about this than I do could comment.
The argument is, "This can be done now, or soon, while a vaccine will take 12 - 18 months, if not longer."
Immunodepressed subjects right now are protected by isolation and by the fact that right now a smallish percentage of the general population is an asymptomatic carrier, if we were to start spreading this actively those variables would change.
But the author is doing himself a disservice by saying that tens of millions of people worldwide will die.
And why is it a bad thing to have to be vaccinated on a yearly basis, poor African countries have not been hit hard that is a fact.
The areas being hit the hardest can afford to be vaccinated yearly and is accustomed to it with the yearly flu shot.
Other than that, keep up the good work !
We're officially at almost hundred thousand dead now, most places on Earth haven't reached peak infections yet, and it's an open secret that deaths are being underreported everywhere. I can easily see tens of millions of dead in few weeks.
Those people should stay at home and practice distancing.
TLDR the virus mutates too quickly for this to be safe.
" There are many ways to make vaccines, and the oldest one is to take the wild-type pathogen, and either ‘break’ it (‘attenuate it’), or find an example in nature that’s messed up and can’t cause disease.
The initial smallpox vaccine was cowpox: Close enough to human smallpox that it elicited protective immune responses, but too maladapted to humans that it couldn’t thrive in us, and would be caught by the slow-walking cops of our immune system.
The strategy used for many of the 1950s/60s-era vaccines was to isolate the disease-causing pathogen, then in a laboratory force it to grow in progressively more-messed-up circumstances. This would drive evolution of the pathogen to mis-adapted freaks. For example, the mumps isolate was from the daughter of the Merck scientist (Maurice Hilleman), and he grew it in cow cells, then lizard cells, then insect cells (or somesuch, I don’t know exactly). By the end of the process, the thing could still infect humans, but just BARELY.
Nowadays, with molecular biology, we can rationally design the ‘attenuations’, and do knock-outs or modifications.
Which brings me to low-virulence wildtype isolates of SARS-CoV-2 (S2): The root problem here, as with HIV, is it’s a super-fast-evolving RNA virus. Sure, a particular isolate might be low-virulence NOW, but give it a few weeks on a cruise ship and – viola! – nasty bugger ahoy!
When SARS-CoV-1 broke out, years back, it had a high lethality and freaked out the public health experts at the time (in fact, we were writing proposals to get into the research, but then it got contained). At that time, efforts were initiated to make a vaccine, based on the observation that all that was needed with the Bcell production of ‘neutralizing antibodies’. This is the long standard, matching most existing vaccines. So it was a low-weight lift, for vaccine developers (relatively easy-peasy). The project got pretty far along, but then stopped when SARS-CoV-1 disappeared as a threat.
When MERS, then SARS-CoV-2 came along, they resurrected the previous, promising design, based on a slow-evolving vector. But in the case of S2, they discovered that the targeting receptor usage of S2 was significantly different, so the design required a significant re-tune. Even so, the Chinese (I think) did it, injected the first people several weeks back, and I don’t think it works well (too early for formal reports).
S2 is nasty, as HIV is. It is using evolution against us. And because its hypermutable (like the influenza viruses), it’s going to be nearly impossible to make one vaccine that works cycle after cycle. It will continue to evolve, but the subsequent cycles will probably have lower lethality than this first pass (which was completely novel to the human immune system, so we had no ‘herd immunity’ protection). Going forward, it will be hard for highly-virulent forms to transmit if they kill their hosts too quickly, which will select for less-virulent forms.
The trick is to stay alive during this pass. The only mechanism we have to do this is to not get infected. The only way to do that is to not expose ourselves to infected people, or the things they’ve touched.
We’re back to how things were in the 1800s. Better than no science, but about the same as post-epidemiology/cell-theory-of-disease (1890s)
But as I said, this vaccine should be RELATIVELY easy to develop. It doesn’t have to be perfect, it just has to blunt viremia (so that the global pneumonia it causes in your upper/lower respiratory system doesn’t cause aveoloar collapse. In other words, even working a little bit will probably massively lower the death count.
But even an easy-peasy vaccine will take 18 months. There’s just no getting around that, unless you want to inoculate 5 billion people with something that might make the pandemic worse."
I don't have any credentials in this field, but IMHO we should attack the problem from all possible angles, including the search for a natural, less harmful strain.
> Apart from the time it will take to develop, trial, and mass produce a vaccine (12-18 months), it is unlikely that any vaccine will be practicable. The reason why is immunity to respiratory viruses (like corona) doesn’t last long – 6 months to 2 years. We would have to keep vaccinating everyone in the world every year (or maybe every 6 months if we are unlucky). This just isn’t going to work in the real world (especially poor countries) and is one of the reasons we don’t have a vaccine for the coronavirus strains that cause the common cold. Unless we can drive the current dangerous SARS-CoV-2 strains to extinction we are going to have a problem with this disease indefinitely.
Every one of these objections also applies to a less harmful strain.
For example, one reason vaccines don't confer durable immunity to many respiratory infections is because the infectious agents change over time, migrating away from the vaccine response. Well, by the same token, a less deadly strain of such an infectious agent would also change over time at the same rate.
On the other hand if we think a naturally occurring strain would provide stable immunity over a long time, then a human-created vaccine would also be stable for a long time.
There is nothing magical about naturally occurring strains. They work in the body exactly the same way vaccines do. (Which is of course why vaccines work in the first place.)
In this case, the author might under estimate the logistics involved in getting this done. At a minimum, the author does not adequately address the logistical challenges of this endeavor in the context of already challenging testing environments. The "quick & cheap" aspect of this is therefore a claim without support.
It might be a promising line of endeavor, and we should pursue multiple parallel initiatives, but the resources needed to pursue this are highly correlated with the resources needed to perform many of the other initiatives that are also promising. There is a bottleneck. Why should this take precedence over other already promising lines of inquiry?
It's really just a different vaccine approach and this isn't the first person to suggest it. It's been talked about online since February if not before.
Not to say I don't think it's a viable idea and I do think it needs more visibility. As the author states this has worked for other diseases.
At least this next time we'll hopefully have more PPE.
Remember #FlattenTheCurve.
What is true is that it would take waaaay longer to reach herd immunity this way.
Another thing that people usually get wrong is the her immunity concept: from what I understand, it doesn't mean we ALL need to be infected. We just need to be enough, so the virus can't spread anymore.
I believe it's also well established that any measures taken to slow the spread of a new virus will always result in fewer total deaths, in that sense quarantining is much more effective than just being a pause button.
Having more time to develop a vaccine or effective treatments is essential, it doesn't have to be herd immunity. Plus in countries where covid19 rate is low enough, social distancing can be helpful for finding and isolating clusters to suppress the epidemic.
Testing, tracing and quarantine of infected people does work. It requires a bunch of infrastructure that we don't have yet (and in many places still aren't building, which is beyond frustrating). It also requires that the baseline level of the outbreak be small enough that you can catch most of the cases, which thus requires the continued lockdowns until we get back to that level. But it does work.
If life was a Star Trek episode, Picard would be saying "Make it so" right about now.
I would watch that episode. Hell, I'd watch any new episode; unfortunately, the only proper Star Trek we've had since Enterprise stopped airing is The Orville.
Pretty wild to count Enterprise as "real Trek", but not Discovery. And hey, TNG was seminal and I loved it growing up too, but let's be real, it's showing its age quite badly these days.
(I'm not even talking about the inconsistency between traveling faster than light and not moving backwards in time, I'm talking about repeated in-universe demonstrations of time travel mastery)
Of course, the writer's tortured "ethics" might require that everyone has to keep the last couple months of awful memories.
But I know nothing about this subject, so that's probably why...
https://www.worldometers.info/coronavirus/coronavirus-age-se...
The “two strain” theory was debunked the very next day as bad science.
http://virological.org/t/response-to-on-the-origin-and-conti...
I can’t believe that a month later, this bad science is still being circulated, by a purported PhD and former professor.
https://news.ycombinator.com/newsguidelines.html
Users need to follow the rules regardless of how right they are or feel they are. And of course there's the side benefit that if you turn out to be wrong, you at least won't have been a jerk about it.
The article seems to work within the current findings of many mutations and different mutations have varying degrees of impact on people.
Is not the same paper he's pointing to as having found a milder strain: https://www.medrxiv.org/content/10.1101/2020.03.10.20033944v...
What am I missing? Are they both based on a flawed understanding?
I was planning to go through all of his replies to other posters and debunk them one-by-one.
> Yes. Almost all (>99.9%) of people who are infected (and have a mild case) are infected with a dangerous strain of the virus, they just happen to have an immune system that can control the virus well. With COVID-19 a mild case does not mean you are infected with an attenuated strain – for most people with a mild case if they happen to infect a person with preexisting conditions or who is old, that person will be at a high risk of dying. A mild case does not equal a harmless strain.
Even if the weak-strain hypothesis holds water (which remains to be seen), the proposal is predicated on something that's physically impossible to do. Test large numbers of people. Hundreds of millions or even billions.
Then, given those tests, find the weak strains.
That's also the minimum needed to "re-open" the country.
If we could test 20-30% of the population, we'd be in great shape. But we can't and may not ever be able to.
Even if you can test that many, you've got to prove that the weak strain is harmless. Then you've got to figure out how to administer doses safely.
So the solution must work within those parameters. And the only practical option is a vaccine.
> The major risk is the virus we think is safe is not 100% safe. While we can use community spread of the identified strain to estimate how safe it will be (i.e. if it has infected 1000 people and none have got seriously ill then we should have a pretty good idea that it is safe), but our knowledge will be incomplete. We can of course spend the next few years testing and trialling, but if we do this by the time any strain is shown to be 99.999% safe (not even the polio vaccine is 100% safe) we will have all got COVID-19 and the world’s economy will be a smoking ruin.
This guy is absolutely bonkers, or pulling a Swift.
He's proposing the (forced?) infection of a large portion of the population with a live virus that has been through none of the safety protocols established over many decades of catastrophic failures.
This is not how drug testing works. This is not how public health works. This is not how you assess safety. This is not ethical.
This is tech bro medicine at its absolute worst.
If it's just a repetition of the previous thread, I'm sorry. Repetition isn't good and that wasn't my intention.
I think this post needs to be removed now